查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863429

細胞和基因治療生物製造CDMO市場按服務類型、治療方法、技術、應用、規模、最終用戶和製程階段分類－全球預測，2025-2032年

Cell & Gene Therapy Biomanufacturing CDMO Market by Service Type, Therapy Type, Technology, Application, Scale, End User, Process Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療生物製造 CDMO 市場將成長至 43.7541 億美元，複合年成長率為 31.63%。

主要市場統計數據
基準年 2024 4.8547億美元
預計年份：2025年 6.4087億美元
預測年份：2032年 43.7541億美元
複合年成長率 (%) 31.63%

相關人員明確指出，大規模生產先進治療方法，必須協調製造能力、監管準備和商業計劃，這是策略上的當務之急。

生物學與製造技術的融合正在重塑先進治療方法從概念到臨床的轉化路徑。基因編輯、載體工程和細胞處理領域的最新突破提升了治療潛力，同時也提高了生產製造的技術和監管門檻。隨著關注點從實驗室規模的創新轉向穩健、可重複的生產，各機構必須重新思考夥伴關係、設施策略和產能投資，以維持臨床應用效率並確保產品品質。

技術、商業和監管方面的變革正迫使合約研發生產機構（CDMO）和開發商尋求整合平台策略，以獲得永續的競爭優勢。

細胞和基因療法生物製造領域正經歷多重融合的變革，這些變革正在重新定義產品的開發、生產和交付方式。載體設計、非病毒遞送方法和封閉式系統處理的技術進步提高了產品的穩健性並降低了污染風險，而分析技術和製程表徵方面的同步進步則使得對產品特性的控制更加精準。這些改進促使申辦方和服務供應商將平台的穩健性和工藝的可重複性置於單純的生產能力之上。

評估2025年關稅變化將如何加劇供應鏈風險，並鼓勵先進治療藥物製造領域的採購多元化和策略性回流

影響關稅和貿易的政策決策會對先進治療方法系統產生連鎖反應，改變成本、進度和供應商關係。 2025年推出的最新關稅政策，為組件、一次性耗材以及某些通常透過複雜的全球供應鏈進口的原料帶來了新的貿易摩擦。這迫使各機構重新評估對供應商的依賴程度、定價策略和庫存政策，以維持專案進度和分析效率。

依服務類型、技術、治療方法和流程階段進行詳細的細分分析，區分能力、監管要求和投資重點。

細緻的細分分析揭示了不同服務類型、治療方法、技術選擇、應用、規模、最終用戶和製程階段的需求差異，從而在整個生態系統中形成了獨特的機會和風險。對服務類型的檢驗表明，分析服務、臨床生產、商業生產和製程開發提供者面臨著不同的需求促進因素：分析服務越來越需要平台化的檢測方法和可比性方面的專業知識；臨床生產側重於快速放大生產規模和CMC製備；商業生產需要永續的產量和成本控制；而製程開發則彌合了藥物發現和可重複生產之間的差距。

區域監管成熟度、製造能力和供應鏈趨勢如何重塑全球市場的夥伴關係模式和投資決策

區域趨勢正在以不同的方式影響製造商、贊助商和服務供應商的策略重點。在美洲，成熟的製造生態系統和完善的法規結構支援計畫快速推進至臨床營運階段。同時，北美供應鏈和契約製造網路集中了病毒和非病毒平台的研發能力。這種環境有利於能夠快速適應並擴展規模以滿足嚴格監管要求的夥伴關係，但也加劇了對人才和專業能力的競爭。

競爭格局概述：規模、專業化和策略聯盟如何決定供應商差異化和長期客戶維繫

先進治療方法生產生態系統的競爭格局複雜多樣，涵蓋了大型傳統合約研發生產機構 (CDMO)、專業載體和細胞療法服務供應商，以及垂直整合的研發生產公司。成熟的契約製造憑藉其規模優勢、豐富的監管經驗和全球覆蓋範圍，展現出卓越的價值，尤其對於即將實現商業化供應的項目而言。同時，專業服務提供者和新興企業則憑藉在特定載體類型、新型給藥方式或客製化製程開發服務方面的深厚技術專長脫穎而出，提供高觸感的服務，從而加速早期專案並降低轉換障礙的風險。

為相關人員提供切實可行的策略性舉措，以降低轉化風險，並為先進治療方法建立穩健、可擴展的生產管道。

領導者應採取果斷行動，彌合科學創新與可製造性之間的鴻溝，優先考慮能夠保障專案進度和病患用藥機會的投資和合作。首先，在專案生命週期的早期階段就應協調製程開發和分析，確保將規模化生產考量和產品發布標準納入產品設計決策。這將有助於制定清晰的技術轉移藍圖，降低下游製程風險，並加快達到監管合規要求的速度。

一種實用且可複製的研究途徑，結合訪談、技術文獻和監管指南，檢驗營運和策略製造方面的洞見。

本研究綜合運用橫斷面分析方法，結合一手和二手研究，對細胞和基因治療生物製造領域的生產趨勢、營運挑戰和策略應對措施進行系統性闡述。一級資訊來源包括對申辦公司和服務供應商的製造、CMC（化學、生產和品管）以及監管部門高級領導進行的結構化訪談。此外，還與製程開發科學家和供應鏈經理進行了技術交流，以了解營運方面的限制和應對措施。這些定性訪談旨在揭示實際決策標準，並協調臨床開發需求與商業性生產要求之間的差異。

從整體角度審視製造策略、監管準備和供應鏈韌性之間的聯繫，將其視為先進治療方法長期成功的核心決定因素。

對技術、營運和策略因素的綜合分析揭示了正在變革時期中的製造業生態系統。雖然科學創新加速了治療潛力的發揮，但對工藝科學、供應鏈韌性和一體化夥伴關係關係的重點投資對於確保潛力的實現至關重要。那些從早期研發階段就協調可擴展製造方法、實現採購和地理風險多元化並建立健全的分析和品質體系的組織，將更有利於在治療方法走向廣泛臨床應用的過程中，保持專案進展勢頭並確保患者獲得治療。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合自動化封閉式反應器系統，以提高細胞療法的可擴展性並降低污染風險
  • 在細胞和基因治療生產中應用數位雙胞胎建模和人工智慧驅動的過程分析，實現生物製程的即時最佳化
  • 擴大同種異體細胞療法契約製造，以滿足不斷成長的全球商業需求
  • 引入一次性感測器技術，用於病毒載體生產中關鍵品質屬性的連續監測和控制
  • CDMO與學術研究機構進行策略合作，加速新型基因編輯平台符合cGMP規範
  • 開發用於分散式細胞療法管理和社區醫院生產的模組化填充密封解決方案
  • 監管協調計劃旨在全球統一CAR-T和基因治療產品的療效評估標準
  • 引入可擴展的質體DNA供應鏈，以支援下一代病毒載體生產的快速規模化。
  • 上游連續培養製程的進步可提高病毒載體產量並降低生產成本
  • 在細胞和基因治療CDMO業務中實施永續性舉措，例如綠色溶劑製程和可再生能源的使用。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 細胞和基因治療生物製造CDMO市場按服務類型分類

  • 分析服務
  • 臨床生產
  • 商業生產
  • 製程開發

9. 按治療方法類型分類的細胞和基因治療生物製造CDMO市場

  • 細胞療法
    • 同種異體移植
    • 自體移植
  • 基因治療

10. 細胞和基因治療生物製造CDMO市場（依技術分類）

  • 非病毒載體
    • 電穿孔
    • 脂質奈米顆粒
  • 病毒載體
    • AAV
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第11章：細胞與基因治療生物製造CDMO市場（依應用領域分類）

  • 循環系統
  • 神經病學
  • 腫瘤學
  • 罕見疾病

第12章：細胞與基因治療生物製造CDMO市場規模

  • 臨床量表
  • 商業規模
  • 臨床前規模

第13章：細胞與基因治療生物製造CDMO市場（依最終用戶分類）

  • 生物製藥公司
  • 受託研究機構
  • 研究所

14. 細胞與基因治療生物製造CDMO市場依製程階段分類

  • 下游工藝
  • 上游工藝

15. 細胞和基因治療生物製造CDMO市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：細胞和基因治療生物製造CDMO市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：各國細胞與基因治療生物製造CDMO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Lonza Group AG
    • Catalent, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fujifilm Diosynth BIoTechnologies USA, Inc.
    • WuXi AppTec Co., Ltd.
    • Charles River Laboratories International, Inc.
    • AGC Biologics, Inc.
    • Samsung Biologics Co., Ltd.
    • Merck KGaA
    • Recipharm AB
Product Code: MRR-5C6F41F5AF94

The Cell & Gene Therapy Biomanufacturing CDMO Market is projected to grow by USD 4,375.41 million at a CAGR of 31.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 485.47 million
Estimated Year [2025] USD 640.87 million
Forecast Year [2032] USD 4,375.41 million
CAGR (%) 31.63%

Framing the strategic urgency for stakeholders to align manufacturing capability, regulatory readiness, and commercial planning for advanced therapies at scale

The intersection of biology and manufacturing is reshaping how advanced therapies move from concept to clinic. Recent breakthroughs in gene editing, vector engineering, and cell processing have elevated therapeutic promise while simultaneously raising the technical and regulatory bar for manufacturing. As attention shifts from lab-scale innovation to robust, reproducible production, organizations must rethink partnerships, facility strategies, and capability investment to sustain clinical throughput and ensure product quality.

These dynamics demand that stakeholders-biopharmaceutical developers, contract manufacturers, investors, and regulators-adopt a strategic lens on capacity, technology fit, and supply chain resiliency. Critical decisions made today about process platforms, vector technologies, and outsourced relationships will determine not only the speed to first-in-human studies but also the ability to scale to broader patient populations. Consequently, executives must balance near-term program needs with long-term platform viability in a landscape where scientific complexity and commercial expectations evolve in parallel.

This summary frames the operational, strategic, and commercial pressures shaping cell and gene therapy biomanufacturing and highlights where targeted action can reduce risk and create value across development and manufacturing lifecycles.

How converging technological, commercial, and regulatory shifts are forcing CDMOs and developers to pursue integrated platform strategies for durable competitive advantage

The biomanufacturing landscape for cell and gene therapies is undergoing several converging shifts that are redefining how products are developed, manufactured, and delivered. Technological progress in vector design, non-viral delivery modalities, and closed-system processing is increasing robustness and reducing contamination risk, while parallel advances in analytics and process characterization are enabling deeper control over product attributes. These improvements are prompting sponsors and service providers to prioritize platform resilience and process reproducibility as much as raw capacity.

Concurrently, commercialization pressures are reshaping business models. The need to de-risk supply and accelerate time to clinic has driven more developers to partner with specialized manufacturing organizations, but those partnerships are evolving beyond transactional capacity provision toward integrated service models that encompass process development, regulatory support, and lifecycle management. This shift is accelerating demand for vertically integrated capabilities that can take a program from vector or cell process definition through clinical and commercial manufacturing under a harmonized quality framework.

Finally, regulatory and reimbursement environments are maturing in many jurisdictions, emphasizing consistent product quality, post-market evidence generation, and supply chain transparency. As a result, successful players are those investing in cross-functional integration-uniting scientific innovation with manufacturing science, regulatory strategy, and commercial planning-to ensure therapies can transition smoothly from proof of concept to sustainable patient access.

Assessing how 2025 tariff shifts in the United States are amplifying supply chain risks, prompting sourcing diversification and strategic onshoring in advanced therapy manufacturing

Policy decisions affecting tariffs and trade can have ripple effects across the advanced therapy ecosystem, altering costs, timelines, and supplier relationships. Recent tariff developments in the United States introduced in 2025 have created new transactional friction for components, single-use consumables, and certain raw materials frequently imported through complex global supply chains. This has led organizations to reassess supplier dependencies, pricing strategies, and inventory policies to preserve program schedules and analytical throughput.

Manufacturers and service providers have responded by diversifying sourcing, qualifying alternate suppliers, and in some cases accelerating onshoring of critical inputs to mitigate exposure. For many stakeholders, the cumulative effect is not just an incremental cost increase but a strategic prompt to re-evaluate the end-to-end supply chain. Decisions about where to locate production capacity or whether to maintain buffer inventories are now being made with an eye toward tariff sensitivity, supplier concentration, and logistical complexity.

Moreover, the policy environment has underscored the value of contractual flexibility and regional redundancy. Sponsors that had pre-existing multi-region supply strategies found it easier to absorb transactional shocks, while those with heavily concentrated supplier networks faced longer lead times to secure alternates. Ultimately, tariff-related pressures are accelerating conversations about supply chain resilience, qualifying secondary sources, and embedding contingency planning into program timelines and vendor selection criteria.

Detailed segmentation analysis that differentiates capability, regulatory needs, and investment priorities across service types, technologies, therapy modalities, and process stages

A nuanced segmentation lens reveals how needs diverge across service types, therapy modalities, technology choices, applications, scales, end users, and process stages, creating distinct opportunity and risk profiles across the ecosystem. When examining service type, providers offering analytical services, clinical manufacturing, commercial manufacturing, and process development are experiencing different demand drivers: analytical services increasingly require platformized assays and comparability expertise, clinical manufacturing focuses on rapid scale-up and CMC readiness, commercial manufacturing demands sustained throughput and cost control, and process development bridges discovery and reproducible manufacturing.

Therapy type further differentiates strategy and operations. Cell therapy and gene therapy programs have divergent material flows and regulatory touchpoints, and within cell therapy, allogeneic models emphasize donor sourcing, banking, and immunogenicity control, while autologous models concentrate on individualized logistics and rapid turnaround. Platform technology influences both cost structure and operational complexity; non-viral vectors such as electroporation and lipid nanoparticles offer alternative manufacturing pathways with distinct analytical packages, whereas viral vector platforms include AAV, adenovirus, lentivirus, and retrovirus-each with specific production, purification, and potency challenges that shape facility design and regulatory dossiers.

Application and therapeutic area impact clinical development and manufacturing priorities. Development for cardiovascular, neurology, oncology, and rare diseases requires tailored potency assays, varying dosing paradigms, and different patient recruitment dynamics that affect batch sizes and release testing strategies. Scale considerations-clinical scale, commercial scale, and preclinical scale-translate directly into capital planning and technology selection, since processes that are fit-for-purpose at one scale may not transition economically to another without significant redevelopment. End users such as biopharmaceutical companies, contract research organizations, and research institutions bring different expectations around service level, documentation, and flexibility, influencing how providers design contracting models and capacity commitments.

Finally, process stage segmentation into upstream and downstream activities highlights where investment and expertise concentrate. Upstream operations drive productivity through cell line or vector production efficiencies, while downstream operations determine purity, yield, and formulation stability. Integrating insights across these segmentation dimensions enables stakeholders to align capabilities, prioritize investments, and select partners that match both program-specific technical needs and broader commercialization objectives.

How regional regulatory maturity, manufacturing capacity, and supply chain dynamics are reshaping partnership models and investment decisions across global markets

Regional dynamics shape strategic priorities for manufacturers, sponsors, and service providers in distinct ways. In the Americas, mature manufacturing ecosystems and established regulatory frameworks support rapid program transitions to clinical operations, while North American supply chains and contract manufacturing networks have concentrated capabilities in both viral and non-viral platforms. This environment favors partnerships that can quickly scale and align with stringent regulatory expectations, but it also intensifies competition for qualified talent and specialized capacity.

Across Europe, the Middle East & Africa, diversity in regulatory approaches and infrastructure maturity creates mixed incentives. European markets emphasize harmonized regulatory alignment and stringent quality systems, while several Middle Eastern and African jurisdictions are in earlier stages of capacity building. These differences encourage cross-border collaborations, distributed manufacturing strategies, and investment in regional centers of excellence that can support local clinical programs and provide redundancy for global operations.

In the Asia-Pacific region, rapid expansion of biotech ecosystems, growing domestic biopharma investment, and evolving regulatory pathways are driving significant capability growth. Local suppliers and CDMOs are increasingly competitive on cost and are investing in technical depth across viral vectors and non-viral modalities. Consequently, many global sponsors are balancing near-term cost considerations with long-term risk management by combining local partnerships for certain activities with established partners in other regions to ensure global regulatory alignment and continuity of supply.

Competitive landscape overview highlighting how scale, specialization, and strategic partnerships determine provider differentiation and long-term client retention

Competitors in the advanced therapy manufacturing ecosystem now span legacy large-scale CDMOs, specialized vector and cell therapy service providers, and vertically integrated developer-manufacturers, creating a diverse competitive landscape. Established contract manufacturers bring scale, regulatory experience, and global footprint, which is particularly valuable for programs approaching commercial supply needs. At the same time, specialized providers and emerging firms differentiate through deep technical expertise in specific vector types, novel delivery modalities, or bespoke process development services, offering high-touch capabilities that can accelerate early-stage programs and de-risk translational hurdles.

Strategic partnerships and M&A activity have been common as organizations seek to close capability gaps and secure capacity. Collaborations between technology licensors, equipment manufacturers, and service providers are enabling faster adoption of automation, single-use technologies, and high-throughput analytics. Additionally, academic spinouts and research institutions continue to be critical sources of innovation, feeding new modalities and process approaches into the commercial supply chain. The competitive imperative is to blend scientific differentiation with operational excellence: firms that can demonstrate reproducible processes, robust quality systems, and flexible capacity will be best positioned to capture long-term customer relationships.

Actionable strategic moves for stakeholders to reduce translational risk and build resilient, scalable manufacturing pathways for advanced therapies

Leaders must act decisively to bridge scientific innovation and manufacturability, prioritizing investments and partnerships that protect program timelines and patient access. First, align process development and analytics early in the program lifecycle to ensure that scale-up considerations and release criteria are embedded into product design decisions. This reduces downstream risk and shortens the path to regulatory readiness by creating a clear technical transfer roadmap.

Second, diversify supplier and component sourcing by qualifying secondary suppliers and exploring regional alternatives for critical consumables. Embedding contingency planning into contracts and procurement strategies minimizes disruption from trade policy shifts or single-source failures. Third, invest in platform technologies and automation that increase reproducibility while lowering per-batch variability; standardized unit operations and modular facility designs can accelerate scale-up and reduce the cost and time of facility commissioning. Fourth, pursue integrated partnership models where process development, clinical manufacturing, and regulatory support are closely coordinated to maintain continuity and accountability across transitions. This approach reduces knowledge loss during tech transfer and improves overall program velocity. Finally, commit to workforce development and cross-functional training to ensure teams can execute complex programs end-to-end, combining technical proficiency with regulatory and quality-system literacy to maintain compliance under evolving regulatory expectations.

Practical and reproducible research approach combining interviews, technical literature, and regulatory guidance to validate operational and strategic manufacturing insights

This research synthesis draws on a multi-channel analysis of primary and secondary inputs to create a coherent view of manufacturing trends, operational challenges, and strategic responses within cell and gene therapy biomanufacturing. Primary inputs include structured interviews with senior manufacturing, CMC, and regulatory leaders across sponsor and service-provider organizations, supplemented by technical dialogues with process development scientists and supply chain managers to understand operational constraints and mitigation strategies. These qualitative engagements were designed to surface real-world decision criteria and to reconcile differences between clinical development imperatives and commercial manufacturing requirements.

Secondary inputs comprised peer-reviewed literature, regulatory guidances, technical white papers, and public disclosures from product developers and service providers to validate technology trends and facility design patterns. Cross-validation techniques were used to triangulate insights from interviews with documented process architectures and regulatory expectations. Attention was paid to reproducibility of technical claims, and areas of high uncertainty are explicitly noted where divergent industry practices remain. The combined approach emphasizes practical relevance, privileging insights that can inform near-term operational planning and strategic partnerships while documenting assumptions and limitations that readers should consider when applying findings to specific programs.

Concluding synthesis that links manufacturing strategy, regulatory readiness, and supply chain resilience as the core determinants of long-term success for advanced therapies

Synthesis of the technical, operational, and strategic threads reveals a manufacturing ecosystem in transition: scientific innovation is accelerating therapeutic possibilities, but realizing those possibilities reliably requires focused investments in process science, supply chain resilience, and integrated partnerships. Organizations that harmonize early-stage development with scalable manufacturing practices, diversify sourcing and regional exposure, and commit to robust analytics and quality systems will be better positioned to sustain program momentum and patient access as therapies move toward broader clinical adoption.

Looking ahead, the interplay of technology choices, regulatory expectations, and commercial realities will continue to shape which programs can be advanced sustainably. Stakeholders that view manufacturing strategy as an enabler of clinical and commercial success-rather than a downstream constraint-will capture disproportionate value. The challenge is to translate technical ingenuity into reproducible, regulatory-ready processes at scale, and the most successful organizations will be those that build integrated roadmaps linking process development, regulatory planning, and supply chain design to deliver therapies reliably to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of automated closed system bioreactors to enhance cell therapy scalability and reduce contamination risk
  • 5.2. Adoption of digital twin modeling and AI-driven process analytics for real-time bioprocess optimization in cell and gene therapy manufacturing
  • 5.3. Expansion of allogeneic cell therapy contract manufacturing capabilities to meet increasing global commercial demand
  • 5.4. Implementation of single-use sensor technologies for continuous monitoring and control of critical quality attributes in viral vector production
  • 5.5. Strategic partnerships between CDMOs and academic labs to accelerate cGMP translation of novel gene editing platforms
  • 5.6. Development of modular fill-finish solutions for decentralized cell therapy administration and local hospital-based manufacturing
  • 5.7. Regulatory alignment efforts toward harmonized global standards for potency assays in CAR-T and gene therapy products
  • 5.8. Adoption of scalable plasmid DNA supply chains to support rapid scale-up of next-generation viral vector production
  • 5.9. Advances in upstream perfusion culture processes to increase yields of viral vectors and reduce production costs
  • 5.10. Incorporation of sustainability initiatives such as green solvent processes and renewable energy use in cell and gene therapy CDMO operations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Clinical Manufacturing
  • 8.3. Commercial Manufacturing
  • 8.4. Process Development

9. Cell & Gene Therapy Biomanufacturing CDMO Market, by Therapy Type

  • 9.1. Cell Therapy
    • 9.1.1. Allogeneic
    • 9.1.2. Autologous
  • 9.2. Gene Therapy

10. Cell & Gene Therapy Biomanufacturing CDMO Market, by Technology

  • 10.1. Non-Viral Vector
    • 10.1.1. Electroporation
    • 10.1.2. Lipid Nanoparticles
  • 10.2. Viral Vector
    • 10.2.1. Aav
    • 10.2.2. Adenovirus
    • 10.2.3. Lentivirus
    • 10.2.4. Retrovirus

11. Cell & Gene Therapy Biomanufacturing CDMO Market, by Application

  • 11.1. Cardiovascular
  • 11.2. Neurology
  • 11.3. Oncology
  • 11.4. Rare Diseases

12. Cell & Gene Therapy Biomanufacturing CDMO Market, by Scale

  • 12.1. Clinical Scale
  • 12.2. Commercial Scale
  • 12.3. Preclinical Scale

13. Cell & Gene Therapy Biomanufacturing CDMO Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Contract Research Organizations
  • 13.3. Research Institutions

14. Cell & Gene Therapy Biomanufacturing CDMO Market, by Process Stage

  • 14.1. Downstream
  • 14.2. Upstream

15. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Cell & Gene Therapy Biomanufacturing CDMO Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Cell & Gene Therapy Biomanufacturing CDMO Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Lonza Group AG
    • 18.3.2. Catalent, Inc.
    • 18.3.3. Thermo Fisher Scientific, Inc.
    • 18.3.4. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • 18.3.5. WuXi AppTec Co., Ltd.
    • 18.3.6. Charles River Laboratories International, Inc.
    • 18.3.7. AGC Biologics, Inc.
    • 18.3.8. Samsung Biologics Co., Ltd.
    • 18.3.9. Merck KGaA
    • 18.3.10. Recipharm AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)

TABL